Trinity Biotech reported $103.71M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Bio-Rad Laboratories USD 9.79B 786.5M Mar/2026
EDAP TMS EUR 61.46M 6.88M Sep/2025
J&J USD 200.89B 1.68B Mar/2026
Mesa Laboratories USD 434.85M 4.5M Dec/2025
OraSure Technologies USD 379.17M 24M Mar/2026
Plus Therapeutics USD 19.92M 3.59M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Siemens EUR 167.97B 2.16B Mar/2026
Surmodics USD 169.82M 8.74M Jun/2025
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026
Tosoh JPY 1.41T 64.61B Mar/2026
Trinity Biotech USD 103.71M 4.08M Sep/2025
Veracyte USD 1.44B 30.38M Mar/2026